Cardica MicroCutter® XCHANGE 30 Named As Finalist In 2014 Medical Design Excellence Awards

   Cardica MicroCutter® XCHANGE 30 Named As Finalist In 2014 Medical Design
                              Excellence Awards

PR Newswire

REDWOOD CITY, Calif., April 28, 2014

REDWOOD CITY, Calif., April 28, 2014 /PRNewswire/ --Cardica, Inc. (Nasdaq:
CRDC) today announced that its MicroCutter^® XCHANGE 30 surgical stapler was
selected as a finalist in the surgical Equipment, Instruments and Supplies
category of the Medical Design Excellence Awards (MDEA), one of the highest
honors in the medical technology industry. The MicroCutter XCHANGE 30 is the
world's smallest articulating surgical stapler, with a five millimeter shaft
diameter and reloadable cartridges. Winners of the awards will be announced on
June 11 in New York.

"The MicroCutter XCHANGE 30, with its small shaft diameter and increased
articulation gives surgeons the ability to maneuver in small spaces, and
represents the first significant reduction in stapler size and improved
functionality in more than a decade," said Mike Chen, M.D., professor of
surgery at University of Alabama School of Medicine and director, Division of
Pediatric Surgery at UAB and Children's Hospital of Alabama. "As we pursue
less invasive surgical options to reduce risk and recovery time for patients,
I believe this device will be instrumental in our ability to perform even less
invasive gastrointestinal procedures. It will be especially useful in infants
and children."

The Medical Design Excellence Awards (MDEA) competition is the MedTech
Industry's Premier Awards Program. Since its inception in 1998, the mission of
the MDEA has been to recognize significant advances in medical product design
and engineering that improve the quality of healthcare delivery and
accessibility. Designed to focus attention upon the complexity of product
development and to showcase examples of what can be achieved when it is well
done, the MDEA celebrates the achievements of medical product manufacturers,
their suppliers, and the many people behind the scenes—engineers, scientists,
designers, and clinicians—who are responsible for the groundbreaking products
that are saving lives, improving patient healthcare, and changing the face of
MedTech.

"We are extremely honored to be named as a finalist for this prestigious
award, as we believe it validates the design, innovation and unique features
offered by the MicroCutter stapler," said Bernard A. Hausen, M.D., Ph.D.,
president and chief executive officer of Cardica. "We continue to innovate
with the goal to provide surgeons with the tools they need to perform even
less invasive procedures than they are today. We look forward to building on
our portfolio of MicroCutter products to introduce a wide range of small,
flexible staplers for a wide variety of surgical procedures."

The MicroCutter XCHANGE 30 is a cartridge-based, minimally-invasive stapling
system with a 5-millimeter shaft diameter and cross sectional area
significantly smaller than 12-millimeter conventional staplers, and with
greater articulation. The size and degree of articulation enhances the
surgeon's access and visualization at the surgical site. Combining several new
technologies, this device is designed to mitigate limitations on surgical
procedures created by larger stapling devices. As the smallest profile
articulating stapler available today, the device may reduce the amount of
tissue dissection and handling to get the stapler in proper position to fire.
The XCHANGE 30 uses reloadable cartridges with a 30mm staple line length and
an integrated knife.

AboutCardica
Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to reduce operating time and facilitate
minimally-invasive and robot-assisted surgeries. Cardica's MicroCutter
XCHANGE^® 30, a cartridge-based articulating surgical stapling device with a
five-millimeter shaft diameter, is manufactured and cleared for use in a
variety of gastrointestinal procedures and appendectomies in the United
States, and is marketed for a wide range of surgical procedures in Europe.
Cardicais developing the Cardica^® MicroCutter XCHANGE^® 45, a
cartridge-based microcutter device with an eight-millimeter shaft to be used
in a variety of procedures, including bariatric, colorectal, thoracic and
general surgery. The Cardica MicroCutter XCHANGE 45 product requires 510(k)
review and CE Mark and is not yet commercially available in the U.S. or
internationally. In addition, Cardica manufactures and markets its automated
anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^®
Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 49,000 units throughout the world.

Forward-Looking Statements
The statements in this press release regarding the benefits expected for
patients from Cardica's MicroCutter XCHANGE 30 and cartridges are
"forward-looking statements." There are a number of important factors that
could cause Cardica's results to differ materially from those indicated by
this forward-looking statement, including: that Cardica may not be successful
in its efforts to commercialize the XCHANGE 30 due to unanticipated technical
or other difficulties; that prospective customers in the United States may not
perceive the benefits of the XCHANGE 30 to be sufficient to warrant its
purchase; that prospective customers in the United States may be constrained
by pricing pressures or purchasing requirements in the hospitals and
facilities in which they work, which could prevent them from purchasing the
XCHANGE 30; as well as other risks detailed from time to time in Cardica's
reports filed with the U.S. Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q for the quarter endedDecember 31, 2013, under
the caption "Risk Factors," filed on February 5, 2014. Cardica expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein. You are
encouraged to read Cardica's reports filed with the U.S. Securities and
Exchange Commission, available at www.sec.gov.

SOURCE Cardica, Inc.

Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
(650) 331-7133, investors@cardica.com
 
Press spacebar to pause and continue. Press esc to stop.